[go: up one dir, main page]

WO2011141929A2 - Compositions pharmaceutiques aqueuses de fluticasone et d'olopatadine - Google Patents

Compositions pharmaceutiques aqueuses de fluticasone et d'olopatadine Download PDF

Info

Publication number
WO2011141929A2
WO2011141929A2 PCT/IN2011/000324 IN2011000324W WO2011141929A2 WO 2011141929 A2 WO2011141929 A2 WO 2011141929A2 IN 2011000324 W IN2011000324 W IN 2011000324W WO 2011141929 A2 WO2011141929 A2 WO 2011141929A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
nasal spray
spray solution
solution
aqueous nasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2011/000324
Other languages
English (en)
Other versions
WO2011141929A3 (fr
Inventor
Sunilendu Bhushan Roy
Kapileswar Swain
Shailesh Arvindbhai Patel
Laxman Magar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of WO2011141929A2 publication Critical patent/WO2011141929A2/fr
Publication of WO2011141929A3 publication Critical patent/WO2011141929A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Definitions

  • the present invention relates to aqueous nasal spray solutions of fluticasone and olopatadine.
  • the present invention relates to a stable aqueous nasal spray solution comprising combination of fluticasone and olopatadine or pharmaceutically acceptable salts thereof and process of manufacturing thereof.
  • the aqueous composition is particularly suitable for topical administration into the nose in the treatment of inflammatory conditions.
  • Inflammatory conditions such as allergic disorders are very prevalent throughout the world, causing a very significant cost to society for therapy and in the form of worker absenteeism and decreased worker productivity. These illnesses are frequently manifested in the form of acute or chronic rhinitis, sometimes also described, respectively, as seasonal and perennial rhinitis.
  • the symptoms of allergic rhinitis may include any number of: reddening of the eyes; ocular secretions; nasal congestion; ocular and palatial irritation; sneezing; and hypersecretion. Symptoms typically occur very promptly following exposure to allergens, of which the most common are grass, pollens and mold spores. The incidence of allergic rhinitis is greater during the spring and summer months, but some persons suffer the symptoms during the entire year, with exacerbations during the spring and summer.
  • rhinitis Several classes of drugs have been utilized for the treatment of inflammatory conditions such as allergic rhinitis, asthma.
  • Intranasal administration of drugs such as corticosteroids and their combinations with antihistaminics are frequently be used to treat nasal symptoms including seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis, recurrent sinusitis, asthma, grass pollen rhinitis, hay fever, snoring, cluster headache, and other diseases and disorders.
  • the nasal administration of drugs allows for their deposition to the nose, sinuses, and other nasal cavities.
  • antihistamines in nasal sprays and eye drops to treat allergy- related conditions.
  • the antihistamine olopatadine usually as hydrochloride salt
  • a corticosteroid which will suppress nasal and ocular inflammatory conditions.
  • corticosteroids known for nasal use are, for example, beclomethasone, mometasone, fluticasone, budesonide and cyclosenide.
  • Corticosteroids known for ocular anti-inflammatory use include betamethasone sodium, dexamethasone sodium and prednisolone acetate, for example.
  • Fluticasone is a synthetic corticosteroid used for the treatment of asthma, allergic rhinitis. It's salt, Fluticasone furoate is having scientific name S-(f!uoromethyl) (6S, 8S, 9R, 10S, 1 1 S, 13S, 14S, 16R, 17R) 6,9-difluoro-l 1, 17-dihydroxy- 10, 13, 16- trimethyl-3-oxo-6,7,8, l l , 12, 14, 15, 16-octahydrocyclopenta[a] phenantrhene -17- carbothiolate. Fluticasone furoate was first disclosed in US Patent No. 6,787,532.
  • fluticasone propionate having scientific name- S-fluoromethyl 6[alpha],9[alpha]-difluoro-ll[beta]-hydroxy-16[alpha]-methyl- 17- propionyloxy-3-oxoandrost-l,4-diene-17[beta]-carbothioate, was first disclosed in US Patent No. 4,335, 121.
  • Olopatadine hydrochloride is a selective histamine Hl-receptor antagonist and it is used for the treatment of ocular symptoms of seasonal allergic conjunctivitis.
  • the compound may be administered in a solid oral dosage form or as an ophthalmic solution.
  • the scientific name of olopatadine hydrochloride is ([(Z)-3- (dimethylamino)propylidene]-6,U-dihydrodibenz[b,e]oxepin-2- acetic acid hydrochloride).
  • Olopatadine hydrochloride was first disclosed in US Patent No. 5, 1 16,863. Olopatadine is stated to be an effective treatment for symptoms of allergic rhinitis and urticaria (e.g., sneezing, nasal discharge and nasal congestion), as well as in the treatment of various skin diseases, such as eczema and dermatitis.
  • olopatadine hydrochloride is commercially available from Alcon under the trademark PATANASE® which is in the form of aqueous nasal spray solution.
  • EP 0780127 A discloses a of glucocorticoid and a leukotriene inhibiting antihistamine with an intranasal carrier.
  • EP 1227812 B discloses use of desloratadine in the manufacture of medicament for treating rhinitis by a combination therapy comprising topical application of desloratadine and mometasone furoate.
  • US Patent Application No. 2009136430 discloses topically administrable formulation for the sustained remission of atopical dermatitis consisting essentially of at least one antihistamine and at least one compound selected from corticosteroids and glucocorticosteroids dissolved in a pharmacologically acceptable carrier.
  • European Patent No. EP 1519731 B discloses a pharmaceutical formulation which comprises azelastine or a salt, solvate or physiologically functional derivatives thereof, and fluticasone or a pharmaceutically acceptable ester thereof.
  • compositions comprising azelastine or pharmaceutically acceptable salts or esters thereof.
  • the patent application also discloses compositions of azelastine and fluticasone or pharmaceutically acceptable salts or esters thereof.
  • WO 97/01337 discloses nasal spray or nasal drops for the treatment of allergic rhinitis are comprising an effective amount of a topical antihistamine; an effective amount of a topical nasal steroid to reduce inflammation and sterile water.
  • Fluticasone furoate For developing suitable nasal formulation of drugs having limited aqueous solubility, such as Fluticasone furoate, it is usually developed in the form of suspension product.
  • fluticasone furoate is commercially available from Glaxosmithkline under the trademark VERAMYST® which is in the form of nasal spray containing aqueous suspension.
  • Fluticasone furoate is also known to possess low systemic bioavailability due to a combination of low aqueous solubility and limited mucosal contact time (Clinical Therapeutics
  • suspension product has limitations of systemic absorption, bioavailability, poor physical stability, dose variation with each administration and need of dispersing or shaking the product before dose administration to avail dose homogeny. Also, there are more issues in scaling up suspension products as compared to the solution products. It is also challenging to devise an aqueous formulation of fluticasone furoate in the form of solution which also renders stability to the formulation over the storage period.
  • a stable aqueous nasal spray solution for topical administration comprising fluticasone, or pharmaceutically acceptable salts thereof and olopatadine, or pharmaceutically acceptable salts thereof, one or more water soluble polymers, and optionally, one or more surfactants.
  • a stable aqueous nasal spray solution for topical administration comprising fluticasone, or pharmaceutically acceptable salts thereof and olopatadine, or pharmaceutically acceptable salts thereof, one or more water soluble polymers, and optionally, one or more surfactants, wherein the solution retains at least 80% potency of fluticasone and olopatadine or pharmaceutically acceptable salts thereof after storage for three months at 40°C and 75% relative humidity.
  • a stable aqueous nasal spray solution for topical administration comprising fluticasone, or pharmaceutically acceptable salts thereof; olopatadine, or pharmaceutically acceptable salts thereof; one or more water soluble polymers; one or more surfactants; one or more chelating agents; one or more preservatives; one or more pH adjusting agents; one or more taste masking agents and optionally one or more pharmaceutically acceptable excipients.
  • a stable aqueous nasal spray solution for topical administration comprising fluticasone, or pharmaceutically acceptable salts thereof, olopatadine, or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients wherein the pH of the composition ranges from about 3.5 to about 7.5.
  • Embodiments of the aqueous nasal spray solution may include one or more of the following features.
  • the aqueous nasal spray solution may include one or more pharmaceutically acceptable excipients selected from water soluble polymers, surfactant, preservatives, chelating agents, pH adjusting agents, sweetener/taste masking agents, and the like.
  • a stable aqueous nasal spray solution for topical administration comprising combination of fluticasone, or pharmaceutically acceptable salts thereof; olopatadine, or pharmaceutically acceptable salts thereof and at least one active agent/s selected from the therapeutic category of corticosteroids, non- steroidal anti-inflammatory agents, antihistaminic agents, decongestants, antiallergic agents; and one or more pharmaceutically acceptable excipients.
  • Embodiments of the aqueous nasal spray solution may include one or more of the following features.
  • the aqueous nasal spray solution may include one or more pharmaceutically acceptable excipients selected from water soluble polymers, surfactant, preservatives, chelating agents, pH adjusting agents, sweetener/taste masking agents and the like.
  • a process for preparing a stable aqueous nasal spray solution for topical administration comprising preparing solution of fluticasone, or pharmaceutically acceptable salts thereof and olopatadine, or pharmaceutically acceptable salts thereof using one or more pharmaceutically acceptable excipients.
  • a process for preparing a stable aqueous nasal spray solution for topical administration comprising preparing solution of fluticasone, or pharmaceutically acceptable salts thereof and olopatadine, or pharmaceutically acceptable salts thereof using one or more water soluble polymers and one or more surfactants and optionally with one or more pharmaceutically acceptable excipients.
  • a process for preparing a stable aqueous nasal spray solution for topical administration comprising fluticasone or pharmaceutically acceptable salts thereof and olopatadine or pharmaceutically acceptable salts the process comprising the steps of-
  • step (b) dispersing surfactant with fluticasone or pharmaceutically acceptable salts thereof and adding to the solution of step (a);
  • step (h) Filling the solution of step (h) into suitable containers.
  • Embodiments of the aqueous nasal spray solution may include one or more of the following features.
  • the nasal spray solution may include one or more pharmaceutically acceptable excipients selected from water soluble polymers, surfactant, preservatives, chelating agents, pH adjusting agents, sweetener/taste masking agents and the like.
  • a method for treating an allergic and/or inflammatory symptom or disorder in a subject in need thereof comprising nasally administering said subject a nasal spray solution comprising fluticasone, or pharmaceutically acceptable salts thereof and olopatadine, or pharmaceutically acceptable salts thereof, one or more water soluble polymers, and optionally, one or more surfactants.
  • Embodiments of the aqueous nasal spray solution may include one or more of the following features.
  • the aqueous nasal spray solution may include one or more pharmaceutically acceptable excipients selected from water soluble polymers, surfactant, preservatives, chelating agents, pH adjusting agents, sweetener/taste masking agents and the like.
  • the inventors of the present invention have surprisingly found that it is possible to develop a stable aqueous nasal spray solution of fluticasone and olopatadine combination by using judicial combination of pharmaceutically acceptable excipients.
  • present inventors have found that a stable pharmaceutical aqueous composition of fluticasone and olopatadine combination can be obtained by using pharmaceutically acceptable excipients comprising one or more water soluble polymer. Further, the inventors of the present invention have found that that the resulting pharmaceutical aqueous composition of fluticasone and olopatadine may remain stable when subjected to storage at accelerated stability conditions.
  • present invention provides a stable aqueous nasal spray solution comprising fluticasone, or pharmaceutically acceptable salts thereof and olopatadine, or pharmaceutically acceptable salts thereof with one or more pharmaceutically acceptable excipients.
  • the present invention further provides a stable aqueous nasal spray solution comprising fluticasone, or pharmaceutically acceptable salts thereof and olopatadine, or pharmaceutically acceptable salts thereof can be obtained by using one or more water soluble polymers. Further the inventors of the present invention have found that that the resulting pharmaceutical aqueous solution may remain stable for at least one month when stored at accelerated stability conditions (e.g. 40°C, 75% relative humidity or 60°C or greater).
  • accelerated stability conditions e.g. 40°C, 75% relative humidity or 60°C or greater.
  • present invention provides a stable aqueous nasal spray solution comprising fluticasone, or pharmaceutically acceptable salts thereof and olopatadine, or pharmaceutically acceptable salts thereof with one or more pharmaceutically acceptable excipients.
  • the present invention further provides a stable aqueous nasal spray solution comprising fluticasone, or pharmaceutically acceptable salts thereof; olopatadine, or pharmaceutically acceptable salts thereof; at least one water soluble polymer with one or more pharmaceutically acceptable excipients.
  • the ratio of the amount of the drug combination to the amount of water soluble polymer present in the aqueous nasal spray solution ranges from about 1 :2 to about 1 :80.
  • fluticasone and olopatadine may be provided as the free base, or in the form of an appropriate pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a pharmaceutically acceptable ' ester, a pharmaceutically acceptable enantiomer, a pharmaceutically acceptable derivative, a pharmaceutically acceptable polymorph or a pharmaceutically acceptable prodrug thereof.
  • Particularly preferred ester of fluticasone is its furoate ester, and particularly preferred salt of olopatadine is its hydrochloride salt.
  • the present invention in particular, provides a stable aqueous nasal spray solution comprising fluticasone, or pharmaceutically acceptable salts thereof; olopatadine, or pharmaceutically acceptable salts thereof; one or more water soluble polymers; optionally one or more surfactants and one or more pharmaceutically acceptable excipients.
  • the ratio of amount of surfactant to the amount of water soluble polymer in the aqueous solution of fluticasone and olopatadine ranges from about 1 :0.01 to about 1 :6.
  • the solvent present in the aqueous nasal spray solution is preferably water or aqueous based solvent.
  • Further solvent constituents that may be present are all solvents which are suitable for nasal administration, in particular alcohols, such as, for example, ethanol, propanol, propanediol or glycerol.
  • the aqueous nasal spray solution preferably comprises water or ethanol/water mixtures as solvent, the solvent more preferably consists of water.
  • a stable aqueous nasal spray solution comprising fluticasone, or pharmaceutically acceptable salts thereof; olopatadine, or pharmaceutically acceptable salts thereof; one or more water soluble polymers; one or more surfactants; one or more chelating agents; one or more preservatives; one or more pH adjusting agents; one or more sweetener/taste masking agents and optionally with one or more pharmaceutically acceptable excipients.
  • suitable water soluble polymers which can be employed in the aqueous nasal spray solution may be selected from, but not limited to polyhydroxy alcohols such as glycerin, polyethylene glycol, propylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, 2-methyl-2,4-pentanediol, 1,2,6-hexanetriol and thioglycol, alginic acid, polyoxyethylene polyoxypropylene glycol, pectin, low methoxyl pectin, guar gum, gum arabic, carrageenan, cellulose derivatives such as- methyl cellulose, carboxymethyl cellulose sodium, xanthan gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose or mixtures thereof.
  • polyhydroxy alcohols such as glycerin, polyethylene glycol, propylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, 2-methyl-2,4-pentanediol, 1,2,
  • the above polyoxyethylene polyoxypropylene glycol is a series of polymers in which ethylene oxide has been addition-polymerized to a polypropylene glycol obtained by polymerization of propylene oxide, and are classified into several types by the difference in the mean degree of polymerization of propylene oxide and ethylene oxide.
  • Particularly preferred water soluble polymers are polyhydroxy alcohols such as polyethylene glycol, propylene glycol, glycerol and cellulose derivatives such as hydroxylpropyl methyl cellulose.
  • the amount of water soluble polymer may ranges from about 0.001% to about 30% w/w relative to the total weight of the solution.
  • combination of water soluble polymers may be used to achieve stable aqueous solution of the present invention. Examples of combination of water soluble polymers include hydroxypropyl methylcellulose - propylene glycol mixture, and polyethylene glycol - propylene glycol mixture.
  • Suitable "surfactants" which can be used for preparing aqueous nasal spray solution may include one or more of anionic, cationic, non-ionic or zwitterionic surfactants.
  • Suitable surfactants which can be employed in the aqueous nasal spray solution may be selected from, but not limited to polyethoxylated sorbitan derivatives such as polysorbates, their ether ethoxylates, produced by reaction of sorbitan esters with ethylene oxide, polyoxyethylene alkyl phenol, polyoxyethylene cetyl ether, polyoxyethylene alkyl-aryl ether, polyoxyethylene monolaurate, polyoxyethylene vegetable oil, polyoxyethylene sorbitan monolaurate, polyoxyethylene esters or mixed fatty and resin acids, polyoxyethylene sorbitol lanolin derivative, polyoxyethylene tridecylether, polyoxyethylene sorbitan esters of mixed fatty and resin acids, polyethoxylated sorbitan derivatives or esters of fatty acids (e.g.,
  • Polysorbates polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, polyoxyethylene monostearate, polyoxyethylene stearyl ether, polyoxyethylene oleyl ether, polyoxyethylene tridecyl ether, polyoxyethylene fatty alcohol, polyoxyethylene alkyl amine, polyoxyethylene glycol monopalmitate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene cetyl ether, polyoxyethylene oxypropylene stearate, polyoxyethylene lauryl ether, polyoxyethylene lanolin derivative, sodium oleate, quaternary ammonium derivative, potassium oleate, N-cetyl N-ethyl morpholinium ethosulfate, sodium lauryl sulfate or mixtures thereof.
  • Particularly preferred surfactants are polyethoxylated sorbitan derivatives.
  • the amount of surfactant may range from about 1% to about 20% w/w relative to the total weight of the solution.
  • the HLB value of the surfactant employed in the aqueous nasal spray solution is approximately 10 or greater.
  • the osmolality can be set by variation of the amounts of the dissolved substances present in the aqueous nasal spray solution besides fluticasone, olopatadine and any further substances present, and/or by addition of an isotonicity agent, preferably a physiologically tolerated salt, such as, for example, sodium chloride or potassium chloride, or a physiologically tolerated polyol, such as, for example, a sugar alcohol, in particular sorbitol or glycerol, in the concentration necessary for rendering isotonic.
  • an isotonicity agent preferably a physiologically tolerated salt, such as, for example, sodium chloride or potassium chloride, or a physiologically tolerated polyol, such as, for example, a sugar alcohol, in particular sorbitol or glycerol, in the concentration necessary for rendering isotonic.
  • the aqueous nasal spray solution of fluticasone and olopatadine has an osmolality of about less than 350 mOsm kg.
  • Examples suitable of the preservatives which can be employed in the aqueous nasal spray solution may be selected from, but not limited to benzyl alcohol, quaternary ammonium halides, phenylcarbinol, thimerosal, disodium edetate. Quaternary ammonium halide preservatives are preferred. Suitable quaternary ammonium halide preservatives include polyquaternium-1 and benzalkonium halides. Preferred benzalkonium halides are benzalkonium chloride and benzalkonium bromide.
  • the amount of the preservative present in the aqueous nasal spray solution may range from about 0.005 to about 0.2% w/w relative to the total weight of the solution. Preferably, the preservative is present at a concentration of about 0.01% relative to the final weight of the solution.
  • Suitable antioxidants which can be employed in the aqueous nasal spray solution may be selected from, but not limited to ascorbic acid, alpha-tocopherol (vitamin-E), butylated hydroxyanisole, butylated hydroxytoluene, glutathione and the like.
  • the amount of the antioxidant present in the aqueous nasal spray solution may ranges from about 0.0002 to about 0.5% w/w relative to the total weight of the solution.
  • the amount of the chelating agent present in the aqueous nasal spray solution of the present invention may range from about 0.0002 to about 0.5% w/w relative to the total weight of the solution.
  • pH adjusting agents which can be employed in the aqueous nasal spray solution may be selected from, but not limited to citric acid, acetic acid, fumaric acid, hydrochloric acid, malic acid, nitric acid, phosphoric acid, propionic acid, sulfuric acid, tartaric acid, phosphate salts, or combinations thereof.
  • the solution of the present invention comprises an amount of a pH adjusting agent sufficient to adjust the pH of the composition to from about 4 to about 7, preferably from about 4.5 to about 6.5 and more preferably from about 3.5 to about 6.5.
  • the amount of pH adjusting agent ranges from about 0.005% to about 1% w/w relative to the total weight of the solution.
  • suitable sweetener/taste masking agents which can be employed in the aqueous nasal spray solution may be selected from, but not limited to sucralose, thaumatin (e.g., Talin (R) ) sucrose, saccharin (including the salt forms: sodium, calcium, etc.), fructose, glucose, dextrose, corn syrup, aspartame, acesulfame-K, xylitol, sorbitol, erythritol, ammonium glycyrrhizinate, thaumatin, neotame, mannitol, eucalyptus oil, camphor, and natural or artificial flavors or flavoring agents (for example menthol, mints, vanilla, orange, etc.), or combinations of two or more of such agents.
  • Particularly preferred taste masking agent is sucralose.
  • the amount of the sweetener/taste masking agent present in the aqueous nasal spray solution may range from about 0.05 to about
  • the aqueous nasal spray solution further may include a crystallization inhibitor.
  • suitable crystallization inhibitors may include, but not limited to hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, poly(2-propenoic acid), and other cellulose derivatives, and combinations of these cellulose derivatives with low viscosity grades.
  • the amount of crystallization inhibitor that can be used may ranges from about 0.01% to about 10.0% w/w relative to the total weight of the solution.
  • composition of the present invention in order to improve the physical properties, appearances, or smells of the composition of the present invention, one or more further pharmaceutically acceptable excipients may be added as desired.
  • the stable aqueous nasal spray solution of fluticasone and olopatadine may comprise one or more additional pharmaceutical active agent/s selected from the therapeutic category of, but not limited to, corticosteroids, non- steroidal antiinflammatory agents, antihistaminic agents, decongestants, antiallergic agents and the like.
  • Suitable corticosteroid may be selected from, but not limited to beclomethasone, flunisolide, triamcinolone, mometasone, budesonide, pharmaceutically acceptable salts thereof and mixtures thereof.
  • Other corticosteroids may be also be selected from aldosterone, beclomethasone, betamethasone, ciclesonide, budesonide, cloprednol, cortisone, cortivazol, deoxycortone, desonide, desoximetasone, dexamethasone, difluorocortolone, fluclorolone, flumethasone, fluocinolone, fluocinonide, fluocortin butyl, fluorocortisone, fluorocortolone, fluorometholone, flurandrenolone, fluticasone, halcinonide, hydrocortisone, icomethasone, meprednisone, methylprednisolone, paramethas
  • Suitable non-steroidal anti-inflammatory agents may be selected from, but not limited to acetaminophen, acetylsalicylic acid, ibuprofen, etodolac, fenbuprofen, fenoprofen, flurbiprofen, indomethacin, ketoprofen, naproxen, oxaprozin, sulindac, etodolac, droxicam, lornoxicam, licofelone pharmaceutically-acceptable salts thereof, optically active racemates thereof and mixtures thereof.
  • Suitable antihistaminic agents may be selected from, but not limited to drug belonging from class of piperazines, phenothiazines, piperidines such as azelastine, cetirizine, loratadine, azelastine, chlorpheniramine, fexofenadine, desloratadine, loratadine, astemizole, cyclizine, bepotastine, promethazine, diphenhydramine, dimenhydrinate, pheniramine, ebastine, levocetirizine, quetiapine, meclizine, ciproxifan, clobenpropit, thioperamide pharmaceutically acceptable salts or mixtures thereof
  • Suitable decongestants may be selected from, but not limited to pseudoephedrine, desoxyephedrine, propylhexedrine, phenylpropanolamine, xylometazoline, phenylephrine, tetrahydrozoline, naphazoline, oxymetazoline, tramazoline and pharmaceutically acceptable salts or mixtures thereof.
  • Suitable antiallergic agents may be selected from but not limited to cromolyn, ketotifen, N-allyl-(dichloro-3, 4-benzyl)-2-methylamino-2-propanol-l, Andolast, oxatamide, nedocromil, emedastine, pyrilamine, levocabastine, and pharmaceutically- acceptable salts or mixtures thereof.
  • the aqueous nasal spray solution can be administered as a drop or any other form suitable for topical administration.
  • the composition may also be administered using a nasal tampon or a nasal sponge.
  • the aqueous nasal spray solution is provided in the form of nasal spray.
  • MDI metered dose inhaler
  • a metered dose inhaler Several types of MDIs are regularly used for administration by inhalation. These types of devices can include breath-actuated MDI, spacer/holding chambers in combination with MDI, and nebulizers.
  • MDI refers to an inhalation delivery system comprising, for example, a canister containing mixture of active agent and a propellant optionally with one or more excipients, a metered dose valve, an actuator, and a mouthpiece.
  • the canister is usually filled with a solution of an active agent, such as the nasal spray composition, and a propellant, such as one or more hydrofluoroalkanes [e.g. 1 , 1 , 1 ,2-tetrafluoroethane (HFA-134a) and 1, 1, 1 ,2,3,3,3-heptafluoropropane (HFA-227)]; chlorofluorocarbons; and alcohols such as ethanol, isopropanol, butanol, propanol or mixtures thereof.
  • a propellant such as one or more hydrofluoroalkanes [e.g. 1 , 1 , 1 ,2-tetrafluoroethane (HFA-134a) and 1, 1, 1 ,2,3,3,3-heptafluoropropane (HFA-227)]; chlorofluorocarbons; and alcohols such as ethanol, isopropanol, butanol, propanol or mixtures thereof.
  • the amount of fluticasone and olopatadine or pharmaceutically acceptable salt thereof is a therapeutically effective amount and can be determined depending on the type and the degree of the disease, the age and the weight of the patient, and the like.
  • the invention further provides a process of preparing the stable aqueous nasal spray solution comprising preparing solution of fluticasone or pharmaceutically acceptable salts thereof and olopatadine or pharmaceutically acceptable salts thereof with one or more pharmaceutically acceptable excipients.
  • the process of preparing the stable aqueous nasal spray solution comprises steps of preparing solution of fluticasone or pharmaceutically acceptable salts thereof and olopatadine or pharmaceutically acceptable salts thereof with one or more water soluble polymers and further addition of one or more pharmaceutically acceptable excipients to the said solution.
  • a process of preparing the stable aqueous nasal spray solution comprising fluticasone or pharmaceutically acceptable salts thereof and olopatadine or pharmaceutically acceptable salts thereof comprises steps of-
  • step (b) dispersing surfactant with fluticasone or pharmaceutically acceptable salts thereof and adding to the solution of step (a);
  • step (d) adding the solution of step (c) into solution of step (b); (e) preparing a solution of olopatadine or pharmaceutically acceptable salts thereof in water;
  • step (h) Filling the solution of step (h) into suitable containers.
  • the clear solution formulations are filled in to commercially available bottles and fit with metered dose pumps for nasal delivery of the drug products.
  • the aqueous solution can, for nasal administration, be applied in all medicament forms which are suitable for nasal administration, such as, for example, nasal drops by means of dispensing devices suitable for this purpose, such as bottles with drop device or nasal spray pumps.
  • the invention further provides a stable aqueous nasal spray solution comprising combination of fluticasone or pharmaceutically acceptable salts thereof and fluticasone or pharmaceutically acceptable salts thereof for use in the preparation of a medicament for treatment of inflammatory disorders comprising administering the said composition to the patient in need thereof.
  • the invention provides a method for treating an allergic and/inflammatory symptom or disorder in a subject in need thereof, comprising: nasally administering to the subject a stable aqueous nasal spray solution comprising a therapeutically effective amount of combination of fluticasone or pharmaceutically acceptable salts thereof and fluticasone or pharmaceutically acceptable salts thereof with one or more pharmaceutically acceptable excipients.
  • a solution of hydroxypropyl methylcellulose was prepared with water. Separately, fluticasone furoate and polysorbate 80 were dispersed and added to the above glycol solution to prepare Fluticasone furoate solution.
  • a bulk solution containing edetate disodium, citric acid monohydrate, sodium Citrate dihydrate and sucralose was prepared with purified water and added to the hydroxypropyl methylcellulose solution followed by addition of fluticasone furoate solution.
  • Olopatadine solution was prepared separately by adding olopatadine hydrochloride to water.
  • a solution of benzalkonium chloride was also prepared separately and added to the olopatadine solution which was then added to the bulk solution containing fluticasone furoate. Finally, the solution was filled into suitable containers.
  • a solution of propylene Glycol and polyethylene glycol was prepared to make glycol solution. Separately, fluticasone furoate and polysorbate 80 were dispersed and added to the above glycol solution to prepare fluticasone furoate solution.
  • a bulk solution containing edetate disodium, citric acid monohydrate, sodium citrate dihydrate and sucralose was prepared with purified water and added to the solution of fluticasone furoate.
  • Olopatadine solution was prepared separately by adding olopatadine hydrochloride to water.
  • a solution of benzalkonium chloride was also prepared separately and added to the olopatadine solution which was then added to the bulk solution containing Fluticasone furoate. Finally, the solution was filled into suitable containers.
  • Stability study of the aqueous nasal spray solution of the present invention was carried out at accelerated stability conditions (40°C, 75% relative humidity (RH) and 60°C) placing containers both in upright (Up) and inverted (Inv) positions. The result indicates that the solution of the present invention remains stable and retains at least 80% potency of fluticasone furoate and olopatadine hydrochloride over the storage period.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des solutions de pulvérisation nasale aqueuses de fluticasone et d'olopatadine. La présente invention concerne en particulier une solution de pulvérisation nasale aqueuse stable qui comprend une combinaison de fluticasone et d'olopatadine ou de sels acceptables sur le plan pharmaceutique de ceux-ci ainsi qu'un procédé de fabrication associé. La composition aqueuse est particulièrement adaptée à une administration topique dans le nez pour le traitement d'états inflammatoires.
PCT/IN2011/000324 2010-05-11 2011-05-10 Compositions pharmaceutiques aqueuses de fluticasone et d'olopatadine Ceased WO2011141929A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1487MU2010 2010-05-11
IN1487/MUM/2010 2010-05-11

Publications (2)

Publication Number Publication Date
WO2011141929A2 true WO2011141929A2 (fr) 2011-11-17
WO2011141929A3 WO2011141929A3 (fr) 2012-03-22

Family

ID=44629755

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000324 Ceased WO2011141929A2 (fr) 2010-05-11 2011-05-10 Compositions pharmaceutiques aqueuses de fluticasone et d'olopatadine

Country Status (1)

Country Link
WO (1) WO2011141929A2 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130210812A1 (en) * 2012-02-10 2013-08-15 Alcon Research, Ltd. Aqueous Pharmaceutical Composition With Enhanced Stability
WO2015036902A1 (fr) 2013-09-13 2015-03-19 Glenmark Pharmaceuticals Ltd Composition pharmaceutique stable à dose fixe comprenant de la mométasone et de l'azélastine
WO2015049665A1 (fr) 2013-10-04 2015-04-09 Glenmark Pharmaceuticals Limited Traitement de la rhinite allergique à l'aide d'une association de mométasone et d'olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
CN106256351A (zh) * 2015-06-18 2016-12-28 江苏吉贝尔药业股份有限公司 盐酸奥洛他定凝胶滴眼液及其制备方法
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
WO2019162902A1 (fr) 2018-02-23 2019-08-29 Glenmark Specialty S.A. Traitement de la rhinite allergique chez des sujets pédiatriques à l'aide d'une combinaison de mométasone et d'olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
CN112656882A (zh) * 2021-01-29 2021-04-16 广东德鑫制药有限公司 一种妇血安薄膜包衣片及其制备方法
WO2021112242A1 (fr) * 2019-12-06 2021-06-10 東興薬品工業株式会社 Composition medicale contenant un compose steroïdique et de l'olopatadine
WO2021112240A1 (fr) * 2019-12-06 2021-06-10 東興薬品工業株式会社 Composition pour gouttes nasales contenant de l'olopatadine
WO2021255622A1 (fr) * 2020-06-15 2021-12-23 Alkem Laboratories Limited Combinaison d'alcaftadine et d'un corticostéroïde
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
US20230277424A1 (en) * 2022-03-03 2023-09-07 Profounda Health And Beauty Inc. Treatment composition for nasal and oral dryness, nosebleeds, and allergy symptoms
CN118557530A (zh) * 2024-08-02 2024-08-30 北京爱力佳医药科技有限公司 一种含盐酸奥洛他定儿童药物组合物及其制备方法
GR1010821B (el) * 2023-11-09 2024-11-15 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Σταθερο ομογενοποιημενο φαρμακευτικο ρινικο εναιωρημα συνδυασμου αζελαστινης και φλουτικαζονης
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335121A (en) 1980-02-15 1982-06-15 Glaxo Group Limited Androstane carbothioates
US5116863A (en) 1986-03-03 1992-05-26 Kyowa Hakko Kogyo Co., Ltd. Dibenz[b,e]oxepin derivative and pharmaceutical compositions thereof
WO1997001337A1 (fr) 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. Combinaison d'antihistamines et de steroides a application topique par voie nasale
EP0780127A1 (fr) 1995-12-19 1997-06-25 The Procter & Gamble Company Pulvérisateur nasale contenant un stéréoide et un antihistamine
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
WO2006058022A1 (fr) 2004-11-24 2006-06-01 Medpointe Healthcare Inc. Compositions comportant de l'azelastine et leurs procedes d'utilisation
EP1227812B1 (fr) 1999-10-08 2007-04-18 Schering Corporation Traitement nasal topique avec la desloratadine et furoate du mometasone
EP1519731B1 (fr) 2002-06-14 2009-04-15 Cipla Ltd. Association d'azelastine et de fluticasone
US20090136430A1 (en) 2007-11-27 2009-05-28 Dugger Harry A Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003291497B2 (en) * 2002-11-12 2007-12-20 Alcon, Inc. The use of an anti-allergy agent and a steroid to treat allergic rhinitis
JP2010531898A (ja) * 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335121A (en) 1980-02-15 1982-06-15 Glaxo Group Limited Androstane carbothioates
US5116863A (en) 1986-03-03 1992-05-26 Kyowa Hakko Kogyo Co., Ltd. Dibenz[b,e]oxepin derivative and pharmaceutical compositions thereof
WO1997001337A1 (fr) 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. Combinaison d'antihistamines et de steroides a application topique par voie nasale
EP0780127A1 (fr) 1995-12-19 1997-06-25 The Procter & Gamble Company Pulvérisateur nasale contenant un stéréoide et un antihistamine
EP1227812B1 (fr) 1999-10-08 2007-04-18 Schering Corporation Traitement nasal topique avec la desloratadine et furoate du mometasone
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
EP1519731B1 (fr) 2002-06-14 2009-04-15 Cipla Ltd. Association d'azelastine et de fluticasone
WO2006058022A1 (fr) 2004-11-24 2006-06-01 Medpointe Healthcare Inc. Compositions comportant de l'azelastine et leurs procedes d'utilisation
US20090136430A1 (en) 2007-11-27 2009-05-28 Dugger Harry A Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALLERGY ASTHMA PROC., vol. 31, no. 2, March 2010 (2010-03-01), pages 132 - 40
CLINICAL THERAPEUTICS, vol. 29, no. 7, July 2007 (2007-07-01), pages 1415 - 1420

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130210812A1 (en) * 2012-02-10 2013-08-15 Alcon Research, Ltd. Aqueous Pharmaceutical Composition With Enhanced Stability
CN104168885A (zh) * 2012-02-10 2014-11-26 爱尔康研究有限公司 具有增强的稳定性的水性药物组合物
US20140364422A1 (en) * 2012-02-10 2014-12-11 Novartis Ag Aqueous Pharmaceutical Composition With Enhanced Stability
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
EP3043773B1 (fr) 2013-09-13 2021-06-30 Glenmark Specialty S.A. Composition pharmaceutique stable à dose fixe comprenant de la mométasone et de l'olopatadine
US9078923B2 (en) 2013-09-13 2015-07-14 Glenmark Pharmaceuticals Limited Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10561672B2 (en) 2013-09-13 2020-02-18 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
EP3718533A1 (fr) 2013-09-13 2020-10-07 Glenmark Specialty S.A. Composition pharmaceutique stable à dose fixe comprenant de la mométasone et de l'azélastine
US9750754B2 (en) 2013-09-13 2017-09-05 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
WO2015036902A1 (fr) 2013-09-13 2015-03-19 Glenmark Pharmaceuticals Ltd Composition pharmaceutique stable à dose fixe comprenant de la mométasone et de l'azélastine
RU2687551C2 (ru) * 2013-09-13 2019-05-15 Гленмарк Спешиалити С.А. Стабильная фармацевтическая композиция с фиксированной дозой, содержащая мометазон и олопатадин
US10376526B2 (en) 2013-09-13 2019-08-13 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10765686B2 (en) 2013-09-13 2020-09-08 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10517880B2 (en) 2013-09-13 2019-12-31 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11400101B2 (en) 2013-10-04 2022-08-02 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10646500B2 (en) 2013-10-04 2020-05-12 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US12064442B2 (en) 2013-10-04 2024-08-20 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
EP4272839A2 (fr) 2013-10-04 2023-11-08 Glenmark Specialty S.A. Traitement de la rhinite allergique à l'aide d'une association de mométasone et d'olopatadine
WO2015049665A1 (fr) 2013-10-04 2015-04-09 Glenmark Pharmaceuticals Limited Traitement de la rhinite allergique à l'aide d'une association de mométasone et d'olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN106256351A (zh) * 2015-06-18 2016-12-28 江苏吉贝尔药业股份有限公司 盐酸奥洛他定凝胶滴眼液及其制备方法
WO2019162902A1 (fr) 2018-02-23 2019-08-29 Glenmark Specialty S.A. Traitement de la rhinite allergique chez des sujets pédiatriques à l'aide d'une combinaison de mométasone et d'olopatadine
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
EP4070791A4 (fr) * 2019-12-06 2023-11-15 Toko Yakuhin Kogyo Co., Ltd. Composition medicale contenant un compose steroïdique et de l'olopatadine
WO2021112240A1 (fr) * 2019-12-06 2021-06-10 東興薬品工業株式会社 Composition pour gouttes nasales contenant de l'olopatadine
JPWO2021112242A1 (fr) * 2019-12-06 2021-06-10
WO2021112242A1 (fr) * 2019-12-06 2021-06-10 東興薬品工業株式会社 Composition medicale contenant un compose steroïdique et de l'olopatadine
CN115701988A (zh) * 2020-06-15 2023-02-14 阿尔克姆实验室有限公司 阿卡他定和皮质类固醇的组合
WO2021255622A1 (fr) * 2020-06-15 2021-12-23 Alkem Laboratories Limited Combinaison d'alcaftadine et d'un corticostéroïde
US20230218630A1 (en) * 2020-06-15 2023-07-13 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid
CN112656882A (zh) * 2021-01-29 2021-04-16 广东德鑫制药有限公司 一种妇血安薄膜包衣片及其制备方法
US20230277424A1 (en) * 2022-03-03 2023-09-07 Profounda Health And Beauty Inc. Treatment composition for nasal and oral dryness, nosebleeds, and allergy symptoms
US12016941B2 (en) * 2022-03-03 2024-06-25 Profounda Health And Beauty Inc. Treatment composition for nasal and oral dryness, nosebleeds, and allergy symptoms
GR1010821B (el) * 2023-11-09 2024-11-15 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Σταθερο ομογενοποιημενο φαρμακευτικο ρινικο εναιωρημα συνδυασμου αζελαστινης και φλουτικαζονης
CN118557530A (zh) * 2024-08-02 2024-08-30 北京爱力佳医药科技有限公司 一种含盐酸奥洛他定儿童药物组合物及其制备方法

Also Published As

Publication number Publication date
WO2011141929A3 (fr) 2012-03-22

Similar Documents

Publication Publication Date Title
WO2011141929A2 (fr) Compositions pharmaceutiques aqueuses de fluticasone et d'olopatadine
EP3043773B1 (fr) Composition pharmaceutique stable à dose fixe comprenant de la mométasone et de l'olopatadine
US8158154B2 (en) Nasal pharmaceutical formulations and methods of using the same
WO2012094283A2 (fr) Compositions de bépostatine
AU2012216890A1 (en) Combination of glycopyrrolate and a beta2 -agonist
JP2006523630A (ja) 鼻用医薬製剤およびその使用方法
CN101951886A (zh) 增强羟甲唑啉的光稳定性
KR20150095896A (ko) 염증성 및/또는 알레르기 질환의 치료를 위한 레보카바스틴 및 플루티카손 푸로에이트의 조합물
US10016443B2 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
TW202228690A (zh) 茚達特羅(indacaterol)之液體調配物
US12064442B2 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
WO2024206662A1 (fr) Formulations liquides d'indacatérol et de glycopyrronium
EP4499099A1 (fr) Formulations liquides d'indacatérol et de glycopyrronium
WO2011135585A2 (fr) Solution pharmaceutique aqueuse de ciclésonide
EP3755375B1 (fr) Traitement de la rhinite allergique chez des sujets pédiatriques à l'aide d'une combinaison de mométasone et d'olopatadine
CN117679423A (zh) 预防或治疗呼吸系统疾病的吸入用药物组合物
US10653661B2 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
RU2798030C2 (ru) Лечение аллергического ринита у субъектов детской возрастной категории с применением комбинации мометазона и олопатадина
HK40033829B (en) Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine
HK40033829A (en) Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine
EA047266B1 (ru) Лечение аллергического ринита у субъектов детской возрастной категории с применением комбинации мометазона и олопатадина
NZ707754B2 (en) Combination of glycopyrrolate and a beta2 -agonist

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11740988

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11740988

Country of ref document: EP

Kind code of ref document: A2